Ayad Hamdan, MD, hematologist and associate professor of medicine at Moores Cancer Center at the University of California, San Diego, discusses a pilot phase I/II trial with brentuximab vedotin (Adcetris) plus chemotherapy in patients with HIV-associated Hodgkin lymphoma.
Michael L. Grossbard, MD, professor in the Department of Medicine, chief of the Hematology and Medical Oncology Inpatient Service at Tisch Hospital, and section chief of Hematology at NYU Langone Health’s Perlmutter Cancer Center, discusses the results of the phase III GALLIUM study in follicular lymphoma.
Ruben Mesa, MD, discusses the utility of fedratinib for patients with myelofibrosis who progress on first-line ruxolitinib.
Srikanth Nagalla, MD, discusses the challenges of managing thrombocytopenia in patients with myeloproliferative neoplasms.
Shella Saint Fleur-Lominy, MD, PhD, discusses the differences between ruxolitinib and fedratinib in the treatment of patients with myeloproliferative neoplasms.
Jonathan A. Ledermann, BSc, MD, FRCP, discusses the additive effects of olaparib (Lynparza) and bevacizumab (Avastin) in advanced ovarian cancer.
Richard T. Penson, MD, MRCP, discusses unexpected findings from the phase III SOLO3 trial and ongoing research with PARP inhibitors in ovarian cancer.
Jonathan D'Cunha, MD, PhD, FACS, discusses surgical options for high-risk patients with lung cancer.
Chad Cherington, MD, discusses the use of immunotherapy and targeted therapy in lung cancer.
Matthew H.G. Katz, MD, FACS, discusses the eligibility criteria for up-front surgery in patients with pancreatic cancer.
Ruben Mesa, MD, discusses the challenges with using JAK inhibitors in myelofibrosis.
Girish Putcha, MD, PhD, discusses the utility of blood-based assays in colorectal cancer.
Dawn L. Hershman, MD, MS, discusses the design of the phase III TAILORx trial in hormone receptor (HR)–positive, HER2-negative breast cancer.
Sameer Desai, MD, discusses current and emerging treatment options under evaluation in lymphomas.
Shubham Pant, MD, discusses exciting data with PARP inhibitors in pancreatic cancer.
Angeles Alvarez Secord, MD, discusses key takeaways from clinical trials that have evaluated frontline maintenance strategies in patients with advanced ovarian cancer.
Emmanuel S. Antonarakis, MBBCh, discusses updated data from the phase II KEYNOTE-199 trial in metastatic castration-resistant prostate cancer.
Tannaz Armaghany, MD, discusses up-front gene sequencing in patients with colorectal cancer.
Jason Westin, MD, MS, FACP, discusses the potential for a chemotherapy-free future in large cell lymphoma.
Luis E. Raez, MD, discusses the role of liquid biopsies in newly diagnosed patients with lung cancer.
Gonzalo Sapisochin, MD, discusses factors that help determine transplant eligibility in hepatocellular carcinoma.
Mira Hellmann, MD, discusses using trametinib to treat patients with low-grade ovarian serous carcinomas.
Terence T. Sio, MD, MS, discusses the standard-of-care dose of radiation therapy in locally advanced, non–small cell lung cancer.
Rana R. McKay, MD, discusses results from an analysis examining the real-world utilization of radium-223 (Xofigo) in metastatic castration-resistant prostate cancer.
Joseph Chao, MD, discusses the utility of microsatellite instability (MSI) status as a prognostic biomarker in gastric and gastroesophageal cancer.
Ryan W. Huey, MD, discusses potential sequencing options with sorafenib among novel combination strategies in hepatocellular carcinoma.
Antonio González-Martín, MD, discusses the design of the PRIMA trial in ovarian cancer.
Toni K. Choueiri, MD, discusses the safety profile of the oral HIF-2α inhibitor MK-6482 in patients with advanced clear cell renal cell carcinoma.
Robert L. Coleman, MD, FACOG, FACS, discusses the results of the phase III VELIA trial examining veliparib in combination with chemotherapy in ovarian cancer.
Richard S. Finn, MD, discusses biomarkers of response to immunotherapy in hepatocellular carcinoma.
